Med-Fine Capital

Investor type Venture Capital
Founders Yujian Zhou


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 30
Average round size
The average size of a deal this fund participated in
Portfolio companies 24
Rounds per year 3.75
Lead investments 10
Follow on index
How often the fund supports its portfolio startups at next rounds
Key employees Soon

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Pharmaceutical
  • Clinical Trials

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Med-Fine Capital:
Typical Co-investors
Med-Fine Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Med-Fine Capital:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Augeo Marketing Minnesota, Saint Paul, United States
Circle Financial Group New York, New York, United States
Confluent Medical Technologies California, Fremont, United States
Curo Capital -
GEM Capital Switzerland, Zürich, Zurich
Hangzhou Longli Touzi Guanli Co., Ltd China, Hangzhou, Zhejiang
ITI Venture Capital Partners Israel, Tel Aviv, Tel Aviv District
Jotter Ventures California, Menlo Park, United States
London Stock Exchange Group England, London, United Kingdom
MAKOTO Japan, Miyagi Prefecture, Sendai Chennai, India, Tamil Nadu
Mt Vernon Investments -
Skycore Massachusetts, United States, Waltham
TMWRK New York, New York, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Allorion Therapeutics

$40M24 Nov 2021 Natick, Massachusetts, United States


Health Care
Virtual Reality
08 Oct 2021 Shangcheng District, Zhejiang, China

Immunophage Biotech

28 Sep 2021 Shanghai, Shanghai, China

LYNK Pharmaceuticals

Health Care
$50M27 Aug 2021 Hangzhou, Zhejiang, China

Life Science
$60M09 May 2021 Shanghai, China

Artivila Therapeutics

Artificial Intelligence
Health Care
$23M30 Mar 2021 Shenzhen, Guangdong, China

BioNova Pharma

$25M20 Oct 2020 China, Shanghai

Hanyu Medical

Health Care
Medical Device
$77M13 Aug 2020 China, Shanghai

$20M10 Aug 2020 China, Shanghai
Lynk Pharmaceuticals Closes $50M Series B Financing

– Lynk Pharmaceuticals is a Hangzhou, China-based pharmaceutical R&D company.
– The company completed Series B financing of $50m.
– The round was led by Lilly Asia Ventures (LAV) with participation from New Alliance Capital and Hangzhou HEDA Biological Medicine Venture Capital Partnership (L.L.P.) and its original shareholders Legend Capital and Med-Fine Capital.
– The new investment will be used to conduct Phase I and II clinical trials for multiple programs in the R&D pipeline, expand international business, strengthen international collaborations with companies and support preclinical development of new projects.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Med-Fine Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: